Johnson & Johnson

Johnson & Johnson MedTech Announces New Clinical Data for the MONARCH

28 May 2025

Largest multi-center prospective robotically-assisted bronchoscopy (RAB) study to date contributes to cannon of scientific evidence and advances clinical understanding

Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025

15 May 2025

23 abstracts, including three late-breaking data presentations, to underscore the company’s scientific leadership in IVL and Reducer technology and the strength of its portfolio

Johnson & Johnson to Participate in the Goldman Sachs 46

15 May 2025

What are clinical trials?

14 May 2025

Learn about the key aspects of clinical trials, the different clinical trial phases and the importance of clinical trial diversity.

New Breast Implant Closes the Reconstruction Gapfor 1 in 7 Women After Breast Cancer Surgery

13 May 2025

MENTOR™ MemoryGel™ Enhance Breast Implants are the first and only implant designed to meet the reconstruction needs of women with larger breast sizes who have undergone a mastectomy Patients who previ

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

09 May 2025

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demon

Johnson & Johnson expands efforts to champion the nursing workforce globally

08 May 2025

New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges

Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers

07 May 2025

Celebrate National Nurses Week with two Johnson & Johnson oncology nurses making a difference in cancer care and patient support.

Johnson & Johnson’s New “Oncology Care Index” Highlights the Growing Divide Between Cancer Innovation and Implementation in Clinical Practice

05 May 2025

73% of surveyed HCPs say there’s a gap between the availability of new, cutting-edge treatments and their successful implementation in clinical practice; 3 in 4 oncologists find the pace of new treatm

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

05 May 2025

TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of

View details about the software product Informachine News Trackers